CORDIS - EU research results

Ubiquitous Pharmacogenomics (U-PGx): Making actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen

Project description

Advancing personalised medicine through pharmacogenomics

Pharmacogenomics is a field of study that aims to understand how an individual's genetic makeup influences their response to drugs. By analysing an individual's genetic variations, pharmacogenomics seeks to develop personalised medicine approaches that can improve drug efficacy and minimise adverse reactions. It also plays a key role in drug development by helping identify patient subgroups that are more likely to benefit from a particular drug. The EU-funded U-PGx project aims to develop a pharmacogenomics approach using health IT solutions that will be tested in terms of feasibility and cost-effectiveness across several European countries. Results will be instrumental to the clinical implementation of pharmacogenomics.


Pharmacogenomics is the study of genetic variability affecting an individual’s response to a drug. Its use allows personalized medicine and reduction in ‘trial and error’ prescribing leading to more efficacious, safer and cost-effective drug therapy. The U-PGx consortium will investigate a pre-emptive genotyping approach (that is: multiple pharmacogenomic variants are collected prospectively and embedded into the patients’ electronic record) of a panel of important pharmacogenomic variants as a new model of personalised medicine. To meet this goal we combine existing pharmacogenomics guidelines and novel health IT solutions. Implementation will be conducted at a large scale in seven existing European health care environments and accounts for the diversity in health system organisations and settings. Feasibility, health outcome and cost-effectiveness will be investigated. We will formulate European strategies for improving clinical implementation of pharmacogenomics based on the findings of this project.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 2 881 388,75
2333 ZA Leiden

See on map

West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek
Activity type
Higher or Secondary Education Establishments
Total cost
€ 2 881 388,75

Participants (21)